Last updated 4 months ago

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

15374 patients around the world

Available in Argentina, Puerto Rico, Mexico, United States, Brazil, Spain

Eli Lilly and Company

90Research sites

15374Patients around the world

This study is for people with

Obesity

From 40 Years

All Gender

: Have a body mass index (BMI) ≥27.0 kilogram/square meter (kg/m ²)
Are either individuals ≥40 years of age with established cardiovascular disease (CVD). CVD is defined as meeting at least one of the following: Coronary artery disease, Cerebrovascular disease, Peripheral arterial disease OR individuals without established CVD but have the presence of cardiovascular (CV) risk factors (primary prevention) women 55-69 years of age or men 50-64 years of age with at least 3 risk factors like tobacco use, dyslipidemia, hypertension at screening, or women ≥70 years of age or men, ≥65 years of age with at least 2 risk factors at screening.

: Have type 1 diabetes (T1D) or (T2D), history of ketoacidosis, or hyperosmolar state/coma
Have laboratory evidence diagnostic of diabetes mellitus at screening of HbA1c ≥6.5% (≥48 millimole/mole (mmol/mol) or fasting glucose (FG) ≥126 milligram/deciliter (≥7.0 millimole/liter (mmol/L).
Any one of the following CV conditions within 90 days prior to screening MI, acute coronary syndrome, stroke, coronary or peripheral arterial revascularization procedure, which may also include carotid artery revascularization, or acute decompensated heart failure
Have a known clinically significant gastric emptying abnormality such as severe gastroparesis or gastric outlet obstruction or have undergone or currently planning any gastric bypass (metabolic) surgery or restrictive bariatric surgery. Note: Liposuction or abdominoplasty are not considered as gastric bypass procedures.
Have a history of chronic or acute pancreatitis
Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Have acute or chronic hepatitis, or clinical signs or symptoms of any other liver disease, or have elevated liver enzyme measurements, determined by the central laboratory at screening
Have a presence or history of malignant neoplasms within the past 5 years prior to screening.